Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹7,737Cr
Rev Gr TTM
Revenue Growth TTM
31.82%
Peer Comparison
Compare up to 10 companies side by side across valuation, profitability, and growth.

YATHARTH
VS
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | | 39.1 | 33.9 | 21.3 | 23.6 | 37.1 | 27.1 | 31.4 | 30.4 | 21.7 | 28.3 | 46.2 |
| 105 | 113 | 126 | 120 | 131 | 158 | 163 | 164 | 175 | 193 | 215 | 246 |
Operating Profit Operating ProfitCr |
| 26.8 | 26.8 | 26.6 | 27.8 | 26.2 | 25.3 | 25.1 | 25.1 | 24.6 | 25.0 | 23.1 | 23.2 |
Other Income Other IncomeCr | 1 | 1 | 4 | 5 | 6 | 4 | 3 | 4 | 5 | 9 | 9 | 8 |
Interest Expense Interest ExpenseCr | 6 | 6 | 3 | 0 | 0 | 3 | 2 | 2 | 1 | 0 | 0 | 1 |
Depreciation DepreciationCr | 8 | 7 | 7 | 8 | 8 | 11 | 16 | 17 | 13 | 15 | 19 | 24 |
| 25 | 29 | 40 | 44 | 44 | 43 | 40 | 40 | 49 | 59 | 55 | 57 |
| 8 | 10 | 12 | 14 | 6 | 13 | 9 | 10 | 10 | 17 | 14 | 14 |
|
Growth YoY PAT Growth YoY% | | 73.1 | 70.4 | 38.8 | 121.4 | 59.6 | 12.1 | 3.4 | 1.0 | 38.4 | 33.3 | 41.3 |
| 12.1 | 12.3 | 16.1 | 17.7 | 21.6 | 14.3 | 14.2 | 13.9 | 16.7 | 16.3 | 14.8 | 13.4 |
| 2.6 | 2.9 | 3.8 | 3.8 | 4.8 | 3.5 | 3.6 | 3.6 | 4.4 | 4.4 | 4.3 | 4.7 |
| Financial Year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|
|
| | 11.4 | 18.0 | 43.4 | 56.6 | 75.3 | 29.8 | 28.9 | 31.3 | 23.7 |
| 60 | 68 | 82 | 108 | 162 | 290 | 387 | 491 | 660 | 829 |
Operating Profit Operating ProfitCr |
| 22.4 | 21.0 | 19.1 | 25.7 | 29.3 | 27.6 | 25.7 | 26.8 | 25.0 | 23.9 |
Other Income Other IncomeCr | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 16 | 16 | 32 |
Interest Expense Interest ExpenseCr | 6 | 5 | 6 | 19 | 19 | 21 | 21 | 9 | 8 | 2 |
Depreciation DepreciationCr | 7 | 6 | 8 | 21 | 21 | 28 | 28 | 29 | 57 | 71 |
| 5 | 8 | 5 | -2 | 28 | 63 | 88 | 157 | 172 | 219 |
| 2 | 2 | 1 | 0 | 9 | 19 | 22 | 42 | 41 | 54 |
|
| | 96.3 | -33.2 | -151.6 | 1,054.1 | 125.5 | 48.9 | 74.1 | 14.0 | 26.5 |
| 3.9 | 6.9 | 3.9 | -1.4 | 8.6 | 11.0 | 12.6 | 17.1 | 14.8 | 15.2 |
| 2.2 | 3.8 | 0.6 | -0.2 | 2.8 | 6.8 | 10.1 | 14.5 | 14.7 | 17.7 |
| Financial Year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|
Equity Capital Equity CapitalCr | 14 | 16 | 16 | 16 | 16 | 66 | 66 | 86 | 96 | 96 |
| 29 | 41 | 39 | 38 | 56 | 51 | 117 | 788 | 1,509 | 1,592 |
Current Liabilities Current LiabilitiesCr | 9 | 10 | 42 | 60 | 55 | 97 | 100 | 67 | 85 | 93 |
Non Current Liabilities Non Current LiabilitiesCr | 86 | 126 | 156 | 165 | 173 | 212 | 203 | 78 | 9 | 43 |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 20 | 28 | 24 | 29 | 49 | 109 | 176 | 510 | 856 | 667 |
Non Current Assets Non Current AssetsCr | 118 | 165 | 233 | 258 | 259 | 317 | 310 | 509 | 875 | 1,189 |
Total Assets Total AssetsCr |
| Financial Year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | 25 | 17 | 17 | 39 | 44 | 60 | 64 | -3 | 150 |
Investing Cash Flow Investing Cash FlowCr | -50 | -51 | -78 | -43 | -21 | -52 | -20 | -226 | -420 |
Financing Cash Flow Financing Cash FlowCr | 26 | 43 | 47 | 5 | -19 | -1 | -18 | 304 | 520 |
|
Free Cash Flow Free Cash FlowCr | 24 | 16 | -60 | -4 | 24 | 21 | 44 | -96 | -161 |
| 822.5 | 287.0 | 439.1 | -1,911.0 | 223.0 | 135.7 | 97.0 | -2.7 | 114.6 |
CFO To EBITDA CFO To EBITDA% | 144.0 | 94.5 | 89.8 | 104.4 | 65.2 | 54.1 | 47.7 | -1.7 | 67.9 |
| Financial Year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3,583 | 4,092 |
Price To Earnings Price To Earnings | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 31.3 | 31.3 |
Price To Sales Price To Sales | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 5.3 | 4.7 |
Price To Book Price To Book | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 4.1 | 2.5 |
| 4.8 | 6.3 | 9.0 | 5.1 | 2.8 | 2.3 | 1.7 | 19.1 | 16.6 |
Profitability Ratios Profitability Ratios |
| 80.6 | 79.8 | 80.9 | 81.7 | 79.7 | 79.7 | 82.1 | 80.1 | 79.7 |
| 22.4 | 21.0 | 19.1 | 25.7 | 29.3 | 27.6 | 25.7 | 26.8 | 25.0 |
| 3.9 | 6.9 | 3.9 | -1.4 | 8.6 | 11.0 | 12.6 | 17.1 | 14.8 |
| 8.4 | 6.9 | 4.9 | 6.6 | 17.7 | 22.2 | 24.2 | 17.3 | 11.1 |
| 7.1 | 10.5 | 7.2 | -3.8 | 27.0 | 37.8 | 36.0 | 13.1 | 8.1 |
| 2.2 | 3.1 | 1.6 | -0.7 | 6.3 | 10.4 | 13.5 | 11.2 | 7.5 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
### **Overview**
Yatharth Hospital & Trauma Care Services Ltd is one of North India’s leading private healthcare providers, specializing in tertiary and quaternary care. Established in 2008, the company has grown rapidly through a combination of organic expansions and strategic acquisitions, currently operating a network of **seven super-specialty hospitals** with a **total bed capacity of over 2,300 beds**, including **640 critical care beds**. The company is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE), having gone public in 2023.
Headquartered in the National Capital Region (NCR), Yatharth has built a dominant presence across **Delhi, Noida, Greater Noida, Faridabad, Haryana, and the Jhansi-Orchha region in Madhya Pradesh**, focusing on high-density urban catchments with underserved healthcare infrastructure.
---
### **Recent Strategic Developments (2023–2025)**
#### **1. Aggressive Expansion via Acquisitions**
Yatharth has significantly expanded its footprint through a series of inorganic growth initiatives:
- **Agra Hospital (Nov 2025):** Acquired 100% stake in a 150-bed multi-specialty hospital (expandable to 250 beds) located on **NH-19 in Agra, Uttar Pradesh**, for **Rs. 260 crores**. The 165,000 sq. ft facility is expected to be integrated into the network in **H2 FY26**, contributing to revenue and EBITDA from day one. It serves a large underpenetrated population and will operate as a **standalone super specialty hub**, offering cardiac surgery, angioplasty, and oncology services.
- **Earlier Acquisitions:**
- **Jhansi-Orchha Hospital (305 beds)** in 2023.
- **Agra Hospital (250 beds)** in 2024.
- In **2025**, acquired three major facilities: a **200-bed Gr. Faridabad** hospital, a **300-bed Delhi (Model Town)** hospital, and a **400-bed Faridabad (Sector 20)** hospital via a **60% stake acquisition** (enterprise value: **Rs. 152 crores**, payment: **Rs. 91 crores**).
These moves position Yatharth as **one of the top 3 hospital chains in North India by bed count**, with a regional concentration that enhances operational synergies.
---
### **Growth Strategy & Capacity Expansion**
Yatharth is executing a dual strategy of **brownfield expansion and greenfield development** with the goal of **3,000 beds by FY28**:
- **Brownfield Expansions:**
- **Greater Noida Hospital:** Expanding from 400 to **600 beds**.
- **Noida Extension Hospital:** Expanding from 450 to **700 beds**.
- **Greenfield Projects:**
- New hospitals in **Delhi Model Town (~300 beds)** and **Faridabad (~400 beds)** are fully registered, possessed, and slated for **Q1 FY26 operationalization**.
- **CAPEX per bed:** ~**Rs. 1 crore**, improved through operational efficiencies.
The company plans to add **~1,200 new beds over the next three years**, prioritizing **high-growth urban centers** in **Uttar Pradesh, Haryana, Punjab, and Bihar**.
---
### **Clinical Excellence & Technology Adoption**
Yatharth is shifting toward **high-acuity, super-specialty care**, driving growth and profitability:
- **Revenue Shift:** Super-specialties now dominate, with **oncology contributing 11% of group revenue** and **~19–20% at Noida Extension**.
- **Centers of Excellence (COEs)** established in **Cardiology, Neurosciences, Oncology, Orthopaedics, Renal Sciences, Gastroenterology, and Spine Care**.
- **Robotic Surgery:** Equipped with **three Da Vinci X Surgical Robots and one Stryker Orthopedic robot**; has completed **over 115 robotic surgeries**.
- **Advanced Technology:** Deployed **Rapid AI for stroke diagnosis, PET-CT, brachytherapy, radiation oncology (Elekta Versa HD), CAR-T cell therapy**, and **3DaVinci and Stryker robotic systems**.
- **Transplant Services:** Offering **kidney, liver, and bone marrow transplants**; Noida Extension Hospital is a designated **Center of Excellence for organ transplants**.
The **Noida Extension Hospital** is the **first in Uttar Pradesh to achieve Joint Commission International (JCI) accreditation**, complementing **NABH/NABL certifications** across all facilities.
---
### **Financial & Operational Performance**
- **Revenue Growth:** Achieved **over 30% YoY revenue growth** in FY25, supported by new hospital ramp-ups.
- **EBITDA Growth:** Over **20% YoY growth**, with strong operating cash flows of **INR 1,496 million** in FY25 and a **70% cash conversion ratio**.
- **Occupancy & ARPOB:**
- Group-wide occupancy improved to **61% in H1 FY25 (from 54% in H1 FY24)**.
- **Average Revenue Per Occupied Bed (ARPOB)** reached **₹38,033 at Noida Extension**, ₹30,721 at Greater Faridabad.
- Strategic shift to **lower government scheme reliance** in new facilities improves revenue quality.
---
### **Medical Value Travel (MVT) / International Expansion**
Yatharth is developing **MVT as a second growth engine**, leveraging the upcoming **Jewar International Airport** (Asia’s largest):
- **Representative Offices:** Established in **Tashkent** and **Baghdad** to serve as MVT hubs for **CIS and West Asia**.
- **Information Centers:** Planned in **Tajikistan, Mauritius, Tanzania, and Kenya**.
- **Outreach:** Conducted **health camps and OPDs** in **Nigeria, Iraq, Uzbekistan, and CIS countries**.
- **Target Regions:** Nigeria, Cameroon, Ethiopia, Mauritius, Uzbekistan, Tajikistan, and Iraq.
- **Dedicated Infrastructure:**
- **200 beds at Greater Noida** for international patients.
- **International patient floor and lounge** at Noida Extension.
- Plans to operate a **clinical examination room at Jewar Airport**.
The company aims to become the **exclusive healthcare partner** for the Jewar Airport, enhancing visibility and patient inflows.
---
### **Funding & Investor Confidence**
- Raised **Rs. 6,250 million** via a **Qualified Institutional Placement (QIP) in Dec 2024**, signaling investor confidence.
- Proceeds allocated to:
- **Medical Equipment (Rs. 2,174 crore)**
- **Funding Acquisitions (Rs. 1,517 crore)**
- **Debt Repayment (Rs. 957 crore)**
- The strong balance sheet supports future **acquisitions and CAPEX investments**.
---
### **Market Position & Competitive Advantage**
- **Geographic Concentration:** Six of seven hospitals in **core NCR urban centers**, enabling shared services, referrals, and branding.
- **High-Density Catchment:** Serves patients from **UP, Delhi, Haryana, Uttarakhand, and neighboring states**.
- **Differentiation:** Focus on **world-class infrastructure, technology, and talent**, with a **low doctor attrition rate** due to a supportive professional environment.
- **Talent Acquisition:** Recruits senior clinicians (‘number twos’) from Apollo, Max, and Fortis, offering leadership roles in new facilities.
- **DNB Residency Program:** Runs across **13 specialties** with ~60 residents, building a future pipeline of super-specialists.